Vanguard Capital Management
ELDN icon

Vanguard Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Vanguard Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Buy
3,417,223
+124,089
+4% +$451K ﹤0.01% 2659
2026
Q1 		$10.1M Buy
+3,293,134
New +$7.76M ﹤0.01% 2724

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Capital Management's ELDN Position: Q2 2026 in Review

Vanguard Capital Management increased its Eledon Pharmaceuticals (ELDN) stake by 3.8% in Q2 2026, buying an estimated $451K and bringing the position to 3,417,223 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2659.

Vanguard Capital Management first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Vanguard Capital Management held 3,417,223 shares of Eledon Pharmaceuticals worth $13.5M as of Q2 2026.
  • Vanguard Capital Management bought 124,089 Eledon Pharmaceuticals shares in Q2 2026, an estimated $451K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2659 holding.
  • Vanguard Capital Management first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.